Incyte Competitors

Amgen (NASDAQ:AMGN) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Earnings & Valuation

This table compares Amgen and Incyte's gross revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Incyte. Amgen is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Amgen has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Incyte has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Profitability

This table compares Amgen and Incyte's net margins, return on equity and return on assets.

Institutional and Insider Ownership

71.7% of Amgen shares are held by institutional investors. Comparatively, 93.4% of Incyte shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 16.1% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Amgen and Incyte, as provided by MarketBeat.com.

Amgen currently has a consensus price target of $254.08, indicating a potential upside of 14.34%. Incyte has a consensus price target of $102.9474, indicating a potential upside of 26.49%. Given Incyte's stronger consensus rating and higher possible upside, analysts clearly believe Incyte is more favorable than Amgen.

Summary

Amgen beats Incyte on 8 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Earnings and Valuation

This table compares Gilead Sciences and Incyte's gross revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than Incyte. Gilead Sciences is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Gilead Sciences has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, Incyte has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Profitability

This table compares Gilead Sciences and Incyte's net margins, return on equity and return on assets.

Institutional & Insider Ownership

77.9% of Gilead Sciences shares are owned by institutional investors. Comparatively, 93.4% of Incyte shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by company insiders. Comparatively, 16.1% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Gilead Sciences and Incyte, as provided by MarketBeat.

Gilead Sciences currently has a consensus price target of $76.1538, indicating a potential upside of 27.16%. Incyte has a consensus price target of $102.9474, indicating a potential upside of 26.49%. Given Gilead Sciences' higher possible upside, equities research analysts plainly believe Gilead Sciences is more favorable than Incyte.

Summary

Gilead Sciences beats Incyte on 8 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Incyte's gross revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Incyte has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Profitability

This table compares Vertex Pharmaceuticals and Incyte's net margins, return on equity and return on assets.

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.4% of Incyte shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 16.1% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Vertex Pharmaceuticals and Incyte, as provided by MarketBeat.

Vertex Pharmaceuticals currently has a consensus price target of $290.5862, indicating a potential upside of 33.38%. Incyte has a consensus price target of $102.9474, indicating a potential upside of 26.49%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Vertex Pharmaceuticals is more favorable than Incyte.

Summary

Vertex Pharmaceuticals beats Incyte on 12 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Earnings and Valuation

This table compares Regeneron Pharmaceuticals and Incyte's gross revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Incyte. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Incyte has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Profitability

This table compares Regeneron Pharmaceuticals and Incyte's net margins, return on equity and return on assets.

Institutional & Insider Ownership

85.9% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.4% of Incyte shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 16.1% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Regeneron Pharmaceuticals and Incyte, as provided by MarketBeat.

Regeneron Pharmaceuticals currently has a consensus price target of $628.52, indicating a potential upside of 20.04%. Incyte has a consensus price target of $102.9474, indicating a potential upside of 26.49%. Given Incyte's higher possible upside, analysts plainly believe Incyte is more favorable than Regeneron Pharmaceuticals.

Summary

Regeneron Pharmaceuticals beats Incyte on 9 of the 14 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Earnings and Valuation

This table compares Biogen and Incyte's gross revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than Incyte. Biogen is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Biogen has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Incyte has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Profitability

This table compares Biogen and Incyte's net margins, return on equity and return on assets.

Institutional & Insider Ownership

78.9% of Biogen shares are owned by institutional investors. Comparatively, 93.4% of Incyte shares are owned by institutional investors. 0.5% of Biogen shares are owned by company insiders. Comparatively, 16.1% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Biogen and Incyte, as provided by MarketBeat.

Biogen currently has a consensus price target of $305.9032, indicating a potential upside of 25.69%. Incyte has a consensus price target of $102.9474, indicating a potential upside of 26.49%. Given Incyte's stronger consensus rating and higher possible upside, analysts plainly believe Incyte is more favorable than Biogen.

Summary

Biogen beats Incyte on 7 of the 13 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Institutional & Insider Ownership

92.0% of Seagen shares are owned by institutional investors. Comparatively, 93.4% of Incyte shares are owned by institutional investors. 31.1% of Seagen shares are owned by company insiders. Comparatively, 16.1% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Seagen and Incyte's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Seagen and Incyte's gross revenue, earnings per share (EPS) and valuation.

Incyte has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Seagen and Incyte, as provided by MarketBeat.

Seagen currently has a consensus price target of $176.75, indicating a potential upside of 5.16%. Incyte has a consensus price target of $102.9474, indicating a potential upside of 26.49%. Given Incyte's higher possible upside, analysts plainly believe Incyte is more favorable than Seagen.

Risk and Volatility

Seagen has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Incyte has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Summary

Incyte beats Seagen on 10 of the 15 factors compared between the two stocks.